DRKS00024765已完成不适用
Effects of altered microcirculation on renal function in transfemoral, transapical, and open aortic valve replacement. - MiNiAKE
Klinik für AnästhesiologieUniversitätsklinikum Heidelberg0 个研究点目标入组 100 人开始时间: 2021年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with aortic valve replacement:
- •- Written informed consent by the study participant
- •- Age = 18 years
- •- Planned aortic valve replacement in the cardiology or cardiosurgery clinic of Heidelberg University Hospital
- •Healthy subjects:
- •- Written informed consent by the study participant
- •- Age = 18 years
排除标准
- •Exclusion criteria common to all study groups:
- •- Failure to meet inclusion criteria.
- •- Infectious viral diseases (HBV, HCV, HIV, COVID-19) or unknown COVID-19 status.
- •- Refusal to participate in the study
- •- Pre-existing severe renal insufficiency with a glomerular (GFR) <15 ml/min/m2 or need for dialysis
研究者
相似试验
已完成
不适用
The effect on the renal functions and blood pressure of DPP-4 Inhibitor for the type 2 diabetic patients .Type 2 diabetesJPRN-UMIN000005337Kanazawa Medical University Diadetes & Endocrinology100
尚未招募
不适用
Microcirculatory and macrocirculatory alterations in different thyroid statescardiac functionmicrovasculature100822061004373910003216NL-OMON40419endocrinologie10
招募中
不适用
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosisJPRN-UMIN000040179Hokkaido University400
招募中
不适用
Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenibRenal cell carcinomaJPRN-UMIN000019393Dokkyo Medical University, Department of Urology30
进行中（未招募）
1 期
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851EUCTR2014-005033-31-FRAddmedica S.A.S